NASDAQ:GLMD - Galmed Pharmaceuticals Stock Price, Forecast & News

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) released its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.32) by $0.11. View Galmed Pharmaceuticals' Earnings History.

Galmed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Galmed Pharmaceuticals.

5 Wall Street analysts have issued twelve-month price targets for Galmed Pharmaceuticals' shares. Their forecasts range from $10.00 to $59.00. On average, they anticipate Galmed Pharmaceuticals' stock price to reach $30.50 in the next year. This suggests a possible upside of 403.3% from the stock's current price. View Analyst Price Targets for Galmed Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galmed Pharmaceuticals.

News stories about GLMD stock have trended extremely negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Galmed Pharmaceuticals earned a media sentiment score of -5.0 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Galmed Pharmaceuticals.

Galmed Pharmaceuticals saw a decline in short interest in November. As of November 29th, there was short interest totalling 438,700 shares, a decline of 9.4% from the November 14th total of 484,000 shares. Based on an average daily trading volume, of 109,200 shares, the days-to-cover ratio is presently 4.0 days. Currently, 3.0% of the shares of the stock are short sold. View Galmed Pharmaceuticals' Current Options Chain.

Some companies that are related to Galmed Pharmaceuticals include Frequency Therapeutics (FREQ), Phathom Pharmaceuticals (PHAT), Stemline Therapeutics (STML), Prothena (PRTA), RAPT Therapeutics (RAPT), Emisphere Technologies (EMIS), MacroGenics (MGNX), Ardelyx (ARDX), Morphic (MORF), Organogenesis (ORGO), Assembly Biosciences (ASMB), Sinovac Biotech (SVA), Akorn (AKRX), DiaMedica Therapeutics (DMCAF) and Catalyst Pharmaceuticals (CPRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include Opko Health (OPK), Rite Aid (RAD), Viking Therapeutics (VKTX), Exelixis (EXEL), Verastem (VSTM), Immunomedics (IMMU), Micron Technology (MU), Conatus Pharmaceuticals (CNAT), Corbus Pharmaceuticals (CRBP) and NVIDIA (NVDA).

Galmed Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Ibex Investors LLC (4.54%), Phoenix Holdings Ltd. (0.12%) and Stifel Financial Corp (0.06%).

GLMD stock was sold by a variety of institutional investors in the last quarter, including Stifel Financial Corp.

GLMD stock was acquired by a variety of institutional investors in the last quarter, including Ibex Investors LLC and Phoenix Holdings Ltd..

Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GLMD stock can currently be purchased for approximately $6.06.

Galmed Pharmaceuticals has a market capitalization of $127.38 million and generates $2.04 million in revenue each year. The biopharmaceutical company earns $-9,860,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. Galmed Pharmaceuticals employs 17 workers across the globe.View Additional Information About Galmed Pharmaceuticals.

The official website for Galmed Pharmaceuticals is http://www.galmedpharma.com/.

Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448.